• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过解释性广义加性模型评估两剂疫苗接种对智利 COVID-19 病例、重症监护病房住院和死亡的减少作用。

Contribution of Two-Dose Vaccination Toward the Reduction of COVID-19 Cases, ICU Hospitalizations and Deaths in Chile Assessed Through Explanatory Generalized Additive Models for Location, Scale, and Shape.

机构信息

Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.

Centro de Excelencia en Capacitación, Investigación y Gestión para la Salud Basada en Evidencia (CIGES), Facultad de Medicina, Universidad de La Frontera, Temuco, Chile.

出版信息

Front Public Health. 2022 Jul 27;10:815036. doi: 10.3389/fpubh.2022.815036. eCollection 2022.

DOI:10.3389/fpubh.2022.815036
PMID:35968462
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9364872/
Abstract

OBJECTIVES

To assess the impact of the initial two-dose-schedule mass vaccination campaign in Chile toward reducing adverse epidemiological outcomes due to SARS-CoV-2 infection.

METHODS

Publicly available epidemiological data ranging from 3 February 2021 to 30 September 2021 were used to construct GAMLSS models that explain the beneficial effect of up to two doses of vaccination on the following COVID-19-related outcomes: new cases per day, daily active cases, daily occupied ICU beds and daily deaths.

RESULTS

Administered first and second vaccine doses, and the statistical interaction between the two, are strong, statistically significant predictors for COVID-19-related new cases per day (R = 0.847), daily active cases (R = 0.903), ICU hospitalizations (R = 0.767), and deaths (R = 0.827).

CONCLUSION

Our models stress the importance of completing vaccination schedules to reduce the adverse outcomes during the pandemic. Future work will continue to assess the influence of vaccines, including booster doses, as the pandemic progresses, and new variants emerge.

POLICY IMPLICATIONS

This work highlights the importance of attaining full (two-dose) vaccination status and reinforces the notion that a second dose provides increased non-additive protection. The trends we observed may also support the inclusion of booster doses in vaccination plans. These insights could contribute to guiding other countries in their vaccination campaigns.

摘要

目的

评估智利最初的两剂大规模疫苗接种运动对减少 SARS-CoV-2 感染不良流行病学结果的影响。

方法

使用从 2021 年 2 月 3 日至 2021 年 9 月 30 日公开的流行病学数据构建 GAMLSS 模型,以解释接种两剂疫苗对以下 COVID-19 相关结局的有益影响:每日新增病例、每日活跃病例、每日占用 ICU 床位和每日死亡人数。

结果

接种第一剂和第二剂疫苗,以及两者之间的统计学相互作用,是 COVID-19 每日新增病例(R = 0.847)、每日活跃病例(R = 0.903)、ICU 住院(R = 0.767)和死亡(R = 0.827)的强有力的、统计学显著的预测指标。

结论

我们的模型强调了完成疫苗接种计划以减少大流行期间不良结局的重要性。随着大流行的发展和新变种的出现,未来的工作将继续评估疫苗的影响,包括加强针。我们观察到的趋势也可能支持在疫苗接种计划中纳入加强针。这些见解可以为指导其他国家的疫苗接种活动提供参考。

政策意义

这项工作强调了实现完全(两剂)疫苗接种状态的重要性,并加强了第二剂提供增加的非附加保护的观点。我们观察到的趋势也可能支持在疫苗接种计划中纳入加强针。这些见解可以为指导其他国家的疫苗接种活动提供参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6993/9364872/8f380a8e433c/fpubh-10-815036-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6993/9364872/6ab78eeb3dd0/fpubh-10-815036-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6993/9364872/8f380a8e433c/fpubh-10-815036-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6993/9364872/6ab78eeb3dd0/fpubh-10-815036-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6993/9364872/8f380a8e433c/fpubh-10-815036-g0002.jpg

相似文献

1
Contribution of Two-Dose Vaccination Toward the Reduction of COVID-19 Cases, ICU Hospitalizations and Deaths in Chile Assessed Through Explanatory Generalized Additive Models for Location, Scale, and Shape.通过解释性广义加性模型评估两剂疫苗接种对智利 COVID-19 病例、重症监护病房住院和死亡的减少作用。
Front Public Health. 2022 Jul 27;10:815036. doi: 10.3389/fpubh.2022.815036. eCollection 2022.
2
Direct impact of COVID-19 vaccination in Chile: averted cases, hospitalizations, ICU admissions, and deaths.智利新冠肺炎疫苗接种的直接影响:避免发病、住院、入住 ICU 和死亡。
BMC Infect Dis. 2024 May 3;24(1):467. doi: 10.1186/s12879-024-09304-1.
3
Statistical explanation of the protective effect of four COVID-19 vaccine doses in the general population.统计解释 4 剂 COVID-19 疫苗在普通人群中的保护作用。
Front Public Health. 2023 Sep 22;11:1253762. doi: 10.3389/fpubh.2023.1253762. eCollection 2023.
4
COVID-19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022.2022 年第一季度,在欧洲 SARS-CoV-2 奥密克戎波期间,COVID-19 疫苗接种率与感染、住院、重症监护病房入院和死亡。
J Med Virol. 2023 Jan;95(1):e28131. doi: 10.1002/jmv.28131. Epub 2022 Sep 14.
5
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.同源和异源加强针对于灭活 SARS-CoV-2 疫苗的有效性:一项大规模前瞻性队列研究。
Lancet Glob Health. 2022 Jun;10(6):e798-e806. doi: 10.1016/S2214-109X(22)00112-7. Epub 2022 Apr 23.
6
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
7
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.COVID-19 病例和住院情况按 COVID-19 疫苗接种状况和既往 COVID-19 诊断情况划分-加利福尼亚州和纽约州,2021 年 5 月至 11 月。
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-131. doi: 10.15585/mmwr.mm7104e1.
8
Boosters and time from the last anti-COVID-19 vaccine dose: lead public health choices by real-time epidemiological assessment.加强针和距上次接种新冠疫苗的时间:通过实时流行病学评估来制定公共卫生决策。
Epidemiol Prev. 2022 Jan-Apr;46(1-2):34-46. doi: 10.19191/EP22.1.A001.001.
9
Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.2021 年 8 月至 10 月,BNT162b2 疫苗第三剂接种与长期护理机构居民 SARS-CoV-2 感染、COVID-19 相关住院和死亡的相关性。
JAMA Netw Open. 2022 Jul 1;5(7):e2219940. doi: 10.1001/jamanetworkopen.2022.19940.
10
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.2021 年 7 月 15 日至 9 月 23 日和 2021 年 12 月 21 日至 2022 年 1 月 27 日期间,加利福尼亚州一家医院因实验室确诊的 SARS-CoV-2 感染住院的成年人的临床特征和结局,期间 B.1.617.2(德尔塔)和 B.1.1.529(奥密克戎)变异株占主导地位。
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223. doi: 10.15585/mmwr.mm7106e2.

引用本文的文献

1
Impact of COVID-19 vaccination on adolescent and youth students' mental health and bullying behaviors after the lifting of COVID-19 restrictions in China.中国解除新冠疫情限制措施后,新冠疫苗接种对青少年学生心理健康及欺凌行为的影响
Front Public Health. 2024 Dec 16;12:1469792. doi: 10.3389/fpubh.2024.1469792. eCollection 2024.
2
Pathophysiological, immunological, and inflammatory features of long COVID.长新冠的病理生理、免疫和炎症特征。
Front Immunol. 2024 Feb 28;15:1341600. doi: 10.3389/fimmu.2024.1341600. eCollection 2024.
3
Statistical explanation of the protective effect of four COVID-19 vaccine doses in the general population.

本文引用的文献

1
Economic Burden of COVID-19: A Systematic Review.新型冠状病毒肺炎的经济负担:一项系统综述
Clinicoecon Outcomes Res. 2022 Apr 28;14:293-307. doi: 10.2147/CEOR.S338225. eCollection 2022.
2
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.同源和异源加强针对于灭活 SARS-CoV-2 疫苗的有效性:一项大规模前瞻性队列研究。
Lancet Glob Health. 2022 Jun;10(6):e798-e806. doi: 10.1016/S2214-109X(22)00112-7. Epub 2022 Apr 23.
3
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.
统计解释 4 剂 COVID-19 疫苗在普通人群中的保护作用。
Front Public Health. 2023 Sep 22;11:1253762. doi: 10.3389/fpubh.2023.1253762. eCollection 2023.
美国奥密克戎、德尔塔和阿尔法 SARS-CoV-2 变异株的 mRNA 疫苗对新冠病毒的临床严重程度和有效性:前瞻性观察研究。
BMJ. 2022 Mar 9;376:e069761. doi: 10.1136/bmj-2021-069761.
4
Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study.在中国广东省疫情期间,灭活 COVID-19 疫苗对 B.1.617.2(德尔塔)变异株引起的疾病的有效性:一项队列研究。
Ann Intern Med. 2022 Apr;175(4):533-540. doi: 10.7326/M21-3509. Epub 2022 Feb 1.
5
Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.由 SARS-CoV-2 灭活疫苗诱导的抗体和 T 细胞对关注变体的识别。
Front Immunol. 2021 Nov 9;12:747830. doi: 10.3389/fimmu.2021.747830. eCollection 2021.
6
Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.匈牙利五种 SARS-CoV-2 疫苗的全国有效性- HUN-VE 研究。
Clin Microbiol Infect. 2022 Mar;28(3):398-404. doi: 10.1016/j.cmi.2021.11.011. Epub 2021 Nov 25.
7
Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine.接种灭活 SARS-CoV-2 疫苗后突破性病例的免疫特征和临床结局。
Front Immunol. 2021 Sep 29;12:742914. doi: 10.3389/fimmu.2021.742914. eCollection 2021.
8
Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina.Gam-COVID-Vac(卫星V疫苗)第一剂对60-79岁患者中确诊的SARS-CoV-2感染、住院和死亡减少的有效性:阿根廷的一项回顾性队列研究
EClinicalMedicine. 2021 Oct;40:101126. doi: 10.1016/j.eclinm.2021.101126. Epub 2021 Sep 12.
9
Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile.在智利的一组健康成年人中使用灭活的严重急性呼吸综合征冠状病毒 2 疫苗的安全性和免疫原性。
Clin Infect Dis. 2022 Aug 24;75(1):e792-e804. doi: 10.1093/cid/ciab823.
10
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.辉瑞-BioNTech 疫苗加强针在以色列预防新冠病毒。
N Engl J Med. 2021 Oct 7;385(15):1393-1400. doi: 10.1056/NEJMoa2114255. Epub 2021 Sep 15.